Sclerotherapy for Infantile Hemangiomas improves adverse effects

Clinical outcomes, resolution rates, and complication rates were compared for 39 patients with hemangiomas and 83 patients with VMs after treatment. The VM group's sclerotherapy data were also examined.

The key findings of this study were:

The three groups' distribution and tissue involvement of lesions, as well as the patients' average age, were substantially different (p < .001).

While it was less in the PG group than in the infantile hemangioma group (p < .0001), the average volume of sclerosing foam delivered each session in VMs was considerably greater than that in the other 2 groups (p < .0001).

However, there was no discernible difference between the 3 groups in terms of overall treatment effectiveness and side effects.

When treating VMs, the utilization of 3% polidocanol and ultrasound-guided foam sclerotherapy rose from superficial to deep lesions, but the use of 1% POL declined (p < .0001).

Reference:

Yang, C., Li, M., Li, X., Zhu, J., & Shu, C. (2023). Foam Sclerotherapy in the Treatment of Hemangiomas and Venous Malformations. In Dermatologic Surgery. Ovid Technologies (Wolters Kluwer Health). https://doi.org/10.1097/dss.0000000000003857